Sommer M, Bachmann C G, Liebetanz K M, Schindehütte J, Tings T, Paulus W
Department of Clinical Neurophysiology, University of Goettingen, Goettingen, Germany.
Acta Neurol Scand. 2007 May;115(5):347-50. doi: 10.1111/j.1600-0404.2007.00796.x.
Restless legs syndrome (RLS) is a common neurological disorder complicated in many patients by augmentation to dopaminergic therapy or comorbidities such as neuropathic pain.
To explore the effectiveness of pregabalin in RLS in a pragmatic clinical setting.
After observing improvement of restless legs symptoms in seven patients treated with pregabalin for neuropathic pain, we extended the clinical observation to a total of 16 patients with secondary RLS, in most of them due to neuropathy, and to three patients with idiopathic RLS.
Three patients discontinued pregabalin because of side effects (rash, fatigue, loss of efficacy). The other 16 patients self-rated a satisfactory or good alleviation of RLS symptoms and maintained pregabalin, five with add-on medication, on a mean daily dose of 305 mg (standard deviation, 185 mg), and with a mean duration of 217 (standard deviation, 183) days.
These data propose pregabalin as a new option in the treatment of secondary RLS for patients with neuropathic pain, which should be further investigated with randomized, placebo-controlled trials.
不安腿综合征（RLS）是一种常见的神经系统疾病，许多患者会因多巴胺能治疗增强或合并症（如神经性疼痛）而病情复杂化。
在实际临床环境中探讨普瑞巴林治疗RLS的有效性。
在观察到7例接受普瑞巴林治疗神经性疼痛的患者不安腿症状有所改善后，我们将临床观察扩展至总共16例继发性RLS患者（其中大多数因神经病变所致）以及3例特发性RLS患者。
3例患者因副作用（皮疹、疲劳、疗效丧失）停用普瑞巴林。其他16例患者自评RLS症状得到满意或良好缓解并继续服用普瑞巴林，其中5例加用了其他药物，平均日剂量为305毫克（标准差185毫克），平均疗程为217天（标准差183天）。
这些数据表明普瑞巴林可作为治疗伴有神经性疼痛的继发性RLS患者的一种新选择，应通过随机、安慰剂对照试验作进一步研究。
